Endobronchial Valve Demonstrates Sustained Improvements for Severe EmphysemaÂ
Researchers found 'statistically significant improvements' in lung function, respiratory symptoms, and quality of life measures at 24 months.
Researchers found 'statistically significant improvements' in lung function, respiratory symptoms, and quality of life measures at 24 months.
Researchers found ‘statistically significant improvements’ in lung function, respiratory symptoms, and quality of life measures at 24 months.
Read MoreNorthwestern Medicine’s Palos Hospital recently conducted its first endobronchial valve procedure using Pulmonx’s Zephyr EBV system.Â
Read MoreThe first randomized controlled trial to compare lung volume reduction surgery and bronchoscopic lung volume reduction (BVLR) via endobronchial valves for people with emphysema has found that both lead to similar improvements in lung function, breathlessness, and exercise capacity.
Read MoreIn RT’s March-April 2022 issue, we go beyond the traditional COPD treatment regimen of pharmaceuticals and supplemental oxygen and explore emerging therapies like targeted lung denervation, lung volume reduction, and endobronchial valves; discuss PICU alarm fatigue and aerosol therapy; and investigate virtual reality simulation.
Read MoreBeyond the traditional regimen of pharmaceuticals and supplemental oxygen, COPD interventions like targeted lung denervation, lung volume reduction, endobronchial valves are emerging.Â
Read MoreLong-term data confirmed the Zephyr Endobronchial Valve provided improvements over baseline in lung function and quality of life out to at least 24 months, and improvements in exercise capacity out to at least 18 months.
Read MoreThe Zephyr Endobronchial Valve is the first minimally-invasive device approved in the United States for treating patients with severe emphysema.
Read MoreAccording to new data, emphysema patients treated with Zephyr Endobronchial Valves had improved breathing, quality of life, and activity, Pulmonx reports.
Read More